{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:10:44Z","timestamp":1792084244949,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Horizon 2020","award":["666992"],"award-info":[{"award-number":["666992"]}]},{"name":"Horizon 2020","award":["666992"],"award-info":[{"award-number":["666992"]}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"crossref","award":["ANR-10-IAIHU-06"],"award-info":[{"award-number":["ANR-10-IAIHU-06"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"crossref","award":["ANR-10-IAIHU-06"],"award-info":[{"award-number":["ANR-10-IAIHU-06"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"crossref","award":["ANR-10-IAIHU-06"],"award-info":[{"award-number":["ANR-10-IAIHU-06"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"crossref","award":["ANR-10-IAIHU-06"],"award-info":[{"award-number":["ANR-10-IAIHU-06"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"crossref","award":["ANR-10-IAIHU-06"],"award-info":[{"award-number":["ANR-10-IAIHU-06"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Research Council","award":["678304"],"award-info":[{"award-number":["678304"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Variability in neurodegenerative disease progression poses great challenges for the evaluation of potential treatments. Identifying the persons who will experience significant progression in the short term is key for the implementation of trials with smaller sample sizes. We apply here disease course mapping to forecast biomarker progression for individual carriers of the pathological CAG repeat expansions responsible for Huntington disease. We used data from two longitudinal studies (TRACK-HD and TRACK-ON) to synchronize temporal progression of 15 clinical and imaging biomarkers from 290 participants with Huntington disease. We used then the resulting HD COURSE MAP to forecast clinical endpoints from the baseline data of 11,510 participants from ENROLL-HD, an external validation cohort. We used such forecasts to select participants at risk for progression and compute the power of trials for such an enriched population. HD COURSE MAP forecasts biomarkers 5\u00a0years after the baseline measures with a maximum mean absolute error of 10 points for the total motor score and 2.15 for the total functional capacity. This allowed reducing sample sizes in trial up to 50% including participants with a higher risk for progression ensuring a more homogeneous group of participants.<\/jats:p>","DOI":"10.1038\/s41598-022-18848-8","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T22:05:36Z","timestamp":1667858736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Forecasting individual progression trajectories in Huntington disease enables more powered clinical trials"],"prefix":"10.1038","volume":"12","author":[{"given":"Igor","family":"Koval","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Dighiero-Brecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan J.","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Tabrizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael I.","family":"Scahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Tezenas du Montcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Durrleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Durr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"key":"18848_CR1","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","volume":"380","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi, S. J. et al. Targeting huntingtin expression in patients with Huntington\u2019s disease. N. Engl. J. Med. 380, 2307\u20132316 (2019).","journal-title":"N. Engl. J. Med."},{"key":"18848_CR2","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/d41573-021-00088-6","volume":"20","author":"K Kingwell","year":"2021","unstructured":"Kingwell, K. Double setback for ASO trials in Huntington disease. Nat. Rev. Drug Discov. 20, 412\u2013413 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"18848_CR3","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates, G. P. et al. Huntington disease. Nat. Rev. Dis. Primers 1, 15005 (2015).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"18848_CR4","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s12035-015-9662-8","volume":"54","author":"Y-M Sun","year":"2017","unstructured":"Sun, Y.-M., Zhang, Y.-B. & Wu, Z.-Y. Huntington\u2019s disease: Relationship between phenotype and genotype. Mol. Neurobiol. 54, 342\u2013348 (2017).","journal-title":"Mol. Neurobiol."},{"key":"18848_CR5","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/ng0893-398","volume":"4","author":"SE Andrew","year":"1993","unstructured":"Andrew, S. E. et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington\u2019s disease. Nat. Genet. 4, 398\u2013403 (1993).","journal-title":"Nat. Genet."},{"key":"18848_CR6","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/mds.26001","volume":"29","author":"JF Gusella","year":"2014","unstructured":"Gusella, J. F., MacDonald, M. E. & Lee, J.-M. Genetic modifiers of Huntington\u2019s disease. Mov. Disord. 29, 1359\u20131365 (2014).","journal-title":"Mov. Disord."},{"key":"18848_CR7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","volume":"65","author":"D Langbehn","year":"2004","unstructured":"Langbehn, D. et al. A new model for prediction of the age of onset and penetrance for Huntington\u2019s disease based on CAG length: Prediction of the age of onset and penetrance for HD. Clin. Genet. 65, 267\u2013277 (2004).","journal-title":"Clin. Genet."},{"key":"18848_CR8","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/ajmg.b.31232","volume":"156","author":"Y Zhang","year":"2011","unstructured":"Zhang, Y. et al. Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am. J. Med. Genet. 156, 751\u2013763 (2011).","journal-title":"Am. J. Med. Genet."},{"key":"18848_CR9","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/mds.26364","volume":"30","author":"JD Long","year":"2015","unstructured":"Long, J. D., Paulsen, J. S., PREDICT\u2010HD Investigators and Coordinators of the Huntington Study Group. Multivariate prediction of motor diagnosis in Huntington\u2019s disease: 12 years of PREDICT-HD. Mov. Disord. 30, 1664\u20131672 (2015).","journal-title":"Mov. Disord."},{"key":"18848_CR10","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/mds.26838","volume":"32","author":"JD Long","year":"2017","unstructured":"Long, J. D. et al. Validation of a prognostic index for Huntington\u2019s disease: Prognostic Index For Huntington\u2019s Disease. Mov. Disord. 32, 256\u2013263 (2017).","journal-title":"Mov. Disord."},{"key":"18848_CR11","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/mds.28222","volume":"35","author":"DR Langbehn","year":"2020","unstructured":"Langbehn, D. R. & Hersch, S. Clinical outcomes and selection criteria for prodromal Huntington\u2019s disease trials. Mov. Disord. 35, 2193\u20132200 (2020).","journal-title":"Mov. Disord."},{"key":"18848_CR12","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/mds.27595","volume":"34","author":"JS Paulsen","year":"2019","unstructured":"Paulsen, J. S., Lourens, S., Kieburtz, K. & Zhang, Y. Sample enrichment for clinical trials to show delay of onset in Huntington disease. Mov. Disord. 34, 274\u2013280 (2019).","journal-title":"Mov. Disord."},{"key":"18848_CR13","first-page":"1","volume":"18","author":"J-B Schiratti","year":"2017","unstructured":"Schiratti, J.-B., Allassonni\u00e8re, S., Colliot, O. & Durrleman, S. A Bayesian mixed-effects model to learn trajectories of changes from repeated manifold-valued observations. J. Mach. Learn. Res. 18, 1\u201333 (2017).","journal-title":"J. Mach. Learn. Res."},{"key":"18848_CR14","doi-asserted-by":"publisher","first-page":"8020","DOI":"10.1038\/s41598-021-87434-1","volume":"11","author":"I Koval","year":"2021","unstructured":"Koval, I. et al. AD course map charts Alzheimer\u2019s disease progression. Sci. Rep. 11, 8020 (2021).","journal-title":"Sci. Rep."},{"key":"18848_CR15","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","volume":"12","author":"SJ Tabrizi","year":"2013","unstructured":"Tabrizi, S. J. et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: Analysis of 36-month observational data. Lancet Neurol. 12, 637\u2013649 (2013).","journal-title":"Lancet Neurol."},{"key":"18848_CR16","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","volume":"8","author":"SJ Tabrizi","year":"2009","unstructured":"Tabrizi, S. J. et al. Biological and clinical manifestations of Huntington\u2019s disease in the longitudinal TRACK-HD study: Cross-sectional analysis of baseline data. Lancet Neurol. 8, 791\u2013801 (2009).","journal-title":"Lancet Neurol."},{"key":"18848_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1474-4422(10)70276-3","volume":"10","author":"SJ Tabrizi","year":"2011","unstructured":"Tabrizi, S. J. et al. Biological and clinical changes in premanifest and early stage Huntington\u2019s disease in the TRACK-HD study: The 12-month longitudinal analysis. Lancet Neurol. 10, 31\u201342 (2011).","journal-title":"Lancet Neurol."},{"key":"18848_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","volume":"11","author":"SJ Tabrizi","year":"2012","unstructured":"Tabrizi, S. J. et al. Potential endpoints for clinical trials in premanifest and early Huntington\u2019s disease in the TRACK-HD study: Analysis of 24 month observational data. Lancet Neurol. 11, 42\u201353 (2012).","journal-title":"Lancet Neurol."},{"key":"18848_CR19","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.ebiom.2015.08.002","volume":"2","author":"S Kl\u00f6ppel","year":"2015","unstructured":"Kl\u00f6ppel, S. et al. Compensation in preclinical Huntington\u2019s disease: Evidence from the track-on HD study. EBioMedicine 2, 1420\u20131429 (2015).","journal-title":"EBioMedicine"},{"key":"18848_CR20","volume-title":"Huntington\u2019s Disease and Insurance I: A Model of Huntington\u2019s Disease","author":"C Gutierrez","year":"2002","unstructured":"Gutierrez, C. & Macdonald, A. Huntington\u2019s Disease and Insurance I: A Model of Huntington\u2019s Disease (Genetics and Insurance Research Centre (GIRC), 2002)."},{"key":"18848_CR21","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/s41598-020-58074-8","volume":"10","author":"P Polosecki","year":"2020","unstructured":"Polosecki, P. et al. Resting-state connectivity stratifies premanifest Huntington\u2019s disease by longitudinal cognitive decline rate. Sci. Rep. 10, 1252 (2020).","journal-title":"Sci. Rep."},{"key":"18848_CR22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.cell.2015.07.003","volume":"162","author":"J-M Lee","year":"2015","unstructured":"Lee, J.-M. et al. Identification of genetic factors that modify clinical onset of Huntington\u2019s disease. Cell 162, 516\u2013526 (2015).","journal-title":"Cell"},{"key":"18848_CR23","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1474-4422(18)30294-1","volume":"17","author":"C Fusilli","year":"2018","unstructured":"Fusilli, C. et al. Biological and clinical manifestations of juvenile Huntington\u2019s disease: A retrospective analysis. Lancet Neurol. 17, 986\u2013993 (2018).","journal-title":"Lancet Neurol."},{"key":"18848_CR24","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/ana.24656","volume":"79","author":"C Bettencourt","year":"2016","unstructured":"Bettencourt, C. et al. DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases: DNA repair pathways modify polyQ disease onset. Ann. Neurol. 79, 983\u2013990 (2016).","journal-title":"Ann. Neurol."},{"key":"18848_CR25","doi-asserted-by":"publisher","first-page":"e64674","DOI":"10.7554\/eLife.64674","volume":"10","author":"R Kacher","year":"2021","unstructured":"Kacher, R. et al. Propensity for somatic expansion increases over the course of life in Huntington disease. Elife 10, e64674 (2021).","journal-title":"Elife"},{"key":"18848_CR26","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.biopsych.2011.07.030","volume":"71","author":"EH Aylward","year":"2012","unstructured":"Aylward, E. H. et al. Striatal volume contributes to the prediction of onset of Huntington disease in incident cases. Biol. Psychiatry 71, 822\u2013828 (2012).","journal-title":"Biol. Psychiatry"},{"key":"18848_CR27","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.psychres.2010.04.030","volume":"178","author":"LJ Beglinger","year":"2010","unstructured":"Beglinger, L. J. et al. Earliest functional declines in Huntington disease. Psychiatry Res. 178, 414\u2013418 (2010).","journal-title":"Psychiatry Res."},{"key":"18848_CR28","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2019.2368","volume":"76","author":"DR Langbehn","year":"2019","unstructured":"Langbehn, D. R. et al. Association of CAG repeats with long-term progression in Huntington disease. JAMA Neurol. 76, 1375 (2019).","journal-title":"JAMA Neurol."},{"key":"18848_CR29","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","volume":"16","author":"LM Byrne","year":"2017","unstructured":"Byrne, L. M. et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: A retrospective cohort analysis. Lancet Neurol. 16, 601\u2013609 (2017).","journal-title":"Lancet Neurol."},{"key":"18848_CR30","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/ana.25171","volume":"83","author":"SL Mason","year":"2018","unstructured":"Mason, S. L. et al. Predicting clinical diagnosis in Huntington\u2019s disease: An imaging polymarker: Predicting clinical diagnosis in HD. Ann. Neurol. 83, 532\u2013543 (2018).","journal-title":"Ann. Neurol."},{"key":"18848_CR31","doi-asserted-by":"publisher","first-page":"8427","DOI":"10.1038\/s41598-020-64643-8","volume":"10","author":"P Widera","year":"2020","unstructured":"Widera, P. et al. Multi-classifier prediction of knee osteoarthritis progression from incomplete imbalanced longitudinal data. Sci. Rep. 10, 8427 (2020).","journal-title":"Sci. Rep."},{"key":"18848_CR32","doi-asserted-by":"publisher","first-page":"21038","DOI":"10.1038\/s41598-020-78212-6","volume":"10","author":"MF Pinto","year":"2020","unstructured":"Pinto, M. F. et al. Prediction of disease progression and outcomes in multiple sclerosis with machine learning. Sci. Rep. 10, 21038 (2020).","journal-title":"Sci. Rep."},{"key":"18848_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0169-2607(97)01803-8","volume":"53","author":"PA Freeborough","year":"1997","unstructured":"Freeborough, P. A., Fox, N. C. & Kitney, R. I. Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput. Methods Programs Biomed. 53, 15\u201325 (1997).","journal-title":"Comput. Methods Programs Biomed."},{"key":"18848_CR34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0895-6111(02)00011-3","volume":"26","author":"VA Magnotta","year":"2002","unstructured":"Magnotta, V. A. et al. Structural MR image processing using the brains2 toolbox. Comput. Med. Imaging Graph. 26, 251\u2013264 (2002).","journal-title":"Comput. Med. Imaging Graph."},{"key":"18848_CR35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fneur.2018.00235","volume":"9","author":"I Koval","year":"2018","unstructured":"Koval, I. et al. Spatiotemporal propagation of the cortical atrophy: Population and individual patterns. Front. Neurol. 9, 235 (2018).","journal-title":"Front. Neurol."},{"key":"18848_CR36","volume-title":"Advances in Neural Information Processing Systems","author":"J-B Schiratti","year":"2015","unstructured":"Schiratti, J.-B., Allassonni\u00e8re, S., Colliot, O. & Durrleman, S. Learning spatiotemporal trajectories from manifold-valued longitudinal data. In Advances in Neural Information Processing Systems Vol. 28 (eds Cortes, C. et al.) (Curran Associates Inc., 2015)."},{"key":"18848_CR37","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1212\/WNL.0000000000004209","volume":"89","author":"SM Hersch","year":"2017","unstructured":"Hersch, S. M. et al. The CREST-E study of creatine for Huntington disease: A randomized controlled trial. Neurology 89, 594\u2013601 (2017).","journal-title":"Neurology"},{"key":"18848_CR38","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S1474-4422(18)30391-0","volume":"18","author":"R Reilmann","year":"2019","unstructured":"Reilmann, R. et al. Safety and efficacy of pridopidine in patients with Huntington\u2019s disease (PRIDE-HD): A phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 18, 165\u2013176 (2019).","journal-title":"Lancet Neurol."},{"key":"18848_CR39","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1212\/WNL.0000000000003478","volume":"88","author":"A McGarry","year":"2017","unstructured":"McGarry, A. et al. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology 88, 152\u2013159 (2017).","journal-title":"Neurology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18848-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18848-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18848-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T22:10:05Z","timestamp":1667859005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18848-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["18848"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-18848-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,7]]},"assertion":[{"value":"24 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors ST and AD are consultants of Roche, that sponsored the recent clinical trial mentioned in the introduction. SD is co-inventor of the patent under reference PCT\/IB2016\/052699. All other authors have nothing to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18928"}}